Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs

被引:57
作者
Yang, Wenying [1 ]
Ji, Qiuhe [2 ]
Zhu, Dalong [3 ]
Yang, Jinkui [4 ]
Chen, Lulu [5 ]
Liu, Zhimin [6 ]
Yu, Demin [7 ]
Yan, Li [8 ]
机构
[1] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
[2] Fourth Mil Med Univ, Xijing Hosp, Dept Endocrinol, Xian 710032, Peoples R China
[3] Nanjing Drum Tower Hosp, Dept Endocrinol, Nanjing, Peoples R China
[4] Beijing Tongren Hosp, Dept Endocrinol, Beijing, Peoples R China
[5] Wuhan Union Hosp, Dept Endocrinol, Wuhan, Peoples R China
[6] Shanghai Changzheng Hosp, Dept Endocrinol, Shanghai, Peoples R China
[7] Tianjin Med Univ, Metab Dis Hosp, Dept Endocrinol, Tianjin, Peoples R China
[8] Zhongshan Univ, Sun Yixian Commemorat Hosp, Dept Endocrinol, Guangzhou, Peoples R China
关键词
D O I
10.2337/dc07-1992
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess the efficacy and safety of twice- and thrice-daily biphasic insulin aspart 30 (BIAsp 30) in Chinese subjects with type 2 diabetes inadequately controlled with oral antidiabetes drugs (OADs). RESEARCH DESIGN AND METHODS - In this 24-week, multicenter, parallel-group, randomized, treat-to-targeL Study, 321 Chinese insulin-naive subjects with poorly controlled type 2 diabetes (fasting blood glucose >= 7.8 mmol/l and AlC >= 7.5 %) were randomized (1:1) to twice- or thrice-daily (BID and TID groups, respectively) BIAsp 30 without OADs. Initial insulin doses were based on fasting blood glucose at randomization. Insulin dose was adjusted with algorithm-controlled titration to achieve premeal blood glucose of 4.4-6.1 mmol/l. RESULTS - AlC decreased significantly in both groups (BID group -2.48 +/- 0.07%; TID group -2.81 +/- 0.07%). Thrice-daily BIAsp 30 showed superiority in AlC improvement (-0.33% 195% CI -0.53 to -0.131; P < 0.01) and helped more subjects achieve AlC targets < 7% (BID group 51.3% vs. TID group 65.8%; P < 0.01). Thrice-daily BIAsp 30 was more effective in subjects with baseline AlC >= 9% (< 7%: BID group 41.5% vs. TID group 58.3%; P < 0.01), There was no significant difference in rates of overall and nocturnal major and minor hypoglycemia per subject year between groups. No significant differences in weight gain (BID group 3.87 +/- 0.28 kg; TID group 4.09 +/- 0.27 kg) and mean daily insulin doses (BID group 0.82 +/- 0.28 units/kg; TID group 0.86 +/- 0.34 units/kg) were observed. CONCLUSIONS - Twice-and thrice-daily BIAsp 30 were effective in Chinese insulin-naive subjects with poorly controlled type 2 diabetes. Thrice-daily BIAsp 30 offered greater reduction in AlC without increasing risk of hypoglycemia, insulin dose, and weight gain, especially in subjects with AlC >= 9%.
引用
收藏
页码:852 / 856
页数:5
相关论文
共 13 条
[1]  
*AM DIAB ASS, 2004, DIABETES CARE S1, V27, pSY4
[2]   Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) [J].
Garber, AJ ;
Wahlen, J ;
Wahl, T ;
Bressler, P ;
Braceras, R ;
Allen, E ;
Jain, R .
DIABETES OBESITY & METABOLISM, 2006, 8 (01) :58-66
[3]  
Home P, 2006, DIABETIC MED, V23, P579
[4]  
Matthews DR, 1998, DIABETIC MED, V15, P297, DOI 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO
[5]  
2-N
[6]   Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients -: Variations with increasing levels of HbA1c [J].
Monnier, L ;
Lapinski, H ;
Colette, C .
DIABETES CARE, 2003, 26 (03) :881-885
[7]   Finding new treatments for diabetes - How many, how fast ... How good? [J].
Nathan, David M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (05) :437-440
[8]  
PAN C, 2006, CURRENT DIABETES CAR
[9]   Prevalence of diabetes and its risk factors in China, 1994 [J].
Pan, XR ;
Yang, WY ;
Li, GW ;
Liu, J .
DIABETES CARE, 1997, 20 (11) :1664-1669
[10]   Initiating insulin therapy in type 2 diabetes - A comparison of biphasic and basal insulin analogs [J].
Raskin, P ;
Hu, P ;
Allen, E ;
Bode, B ;
Hollander, P ;
Garber, A ;
Lewin, A ;
Gabbay, RA .
DIABETES CARE, 2005, 28 (02) :260-265